BioSpace News Archive

Alkeus Pharmaceuticals, Inc., a private, late-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its second quarter 2021 financial results on Wednesday, July 28, 2021 before the U.S. financial markets open.

DolCas Biotech, LLC announces release of pharmacokinetic data in support of the 39-fold-enhanced bioavailability of free curcumin claim for its Curcugen® curcumin extract.

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 fourth-quarter conference call on Wednesday, August 4, 2021, at 3:30 p.m. CT (4:30 p.m. ET).

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2021, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 42 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.

Transcat, Inc., a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it will release its first quarter fiscal year 2022 results after the close of financial markets on Tuesday, July 27, 2021.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Gestalt Diagnostics and Deep Bio today announced their strategic relationship on the development of an integrated workflow for pathologists to use Artificial Intelligence algorithms directly within Gestalt’s PathFlow® platform.

Tthe National Institute for Innovation in Manufacturing Biopharmaceuticals confirms that it has received $153M in new funding from the National Institute of Standards and Technology as announced by U.S. Commerce Secretary Gina Raimondo at NIIMBL’s National Meeting in Washington, DC.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced advancements related to its adenosine analog development platform being developed by Purnovate, Inc., a division of Adial Pharmaceuticals, Inc.